For a 17‑year‑old male with major depressive disorder, anxiety, frequent suicidal ideation, intrusive thoughts, attention‑deficit/hyperactivity disorder and autism spectrum disorder, currently taking mirtazapine 45 mg nightly, sertraline 100 mg daily, propranolol extended‑release 80 mg daily, and Adzenys (amphetamine) 12.5 mg daily, what medication adjustments should be considered?

Medication Adjustments for Treatment-Resistant Depression, Anxiety, and Suicidal Ideation in an Adolescent with ASD and ADHD

Given the persistent severe symptoms (anxiety and depression 8/10) despite dual antidepressant therapy, I recommend increasing sertraline to 150-200 mg daily as the first step, while maintaining close weekly monitoring for suicidal ideation and behavioral activation. 1

Immediate Safety Considerations

• All SSRIs carry a black-box warning for suicidal thinking and behavior in patients under 24 years, with the highest risk during the first 1-2 months of treatment and after dose changes 1, 2
• Weekly monitoring is essential during any medication adjustment, specifically assessing for increased agitation, akathisia, behavioral activation, or worsening suicidality 1
• Amphetamines may increase disinhibition in suicidal adolescents, though they remain appropriate for treating comorbid ADHD 1
• Medication administration must be supervised by a third party who can monitor for mood changes, agitation, or emergency states 1

Primary Recommendation: Optimize Current SSRI Therapy

Sertraline dose escalation is the most evidence-based next step:

• Current dose of 100 mg is below the maximum of 200 mg for adolescents 1
• The American College of Physicians recommends modifying treatment if inadequate response occurs within 6-8 weeks 1
• Increase sertraline by 25-50 mg increments to a target of 150-200 mg daily 1
• Response assessment should occur at 6-8 weeks after reaching target dose 1

Addressing the Mirtazapine-Sertraline Combination

The current dual antidepressant regimen (mirtazapine 45 mg + sertraline 100 mg) is unusual but may be appropriate:

• Mirtazapine at 45 mg is at maximum dose and primarily addresses sleep, though it has shown modest effectiveness for anxiety in autism (34.6% response rate in open studies) 3, 4
• In autism populations, mirtazapine may be preferred over SSRIs for anxiety treatment 5, 6
• However, combining mirtazapine with sertraline increases serotonin syndrome risk, requiring vigilant monitoring for mental status changes, autonomic instability, neuromuscular symptoms, or GI disturbances 2

Alternative Strategies if Sertraline Optimization Fails

Option 1: Switch Antidepressant Strategy

If sertraline reaches 200 mg without adequate response after 8 weeks:

• Consider switching to duloxetine, bupropion, or vortioxetine rather than adding another SSRI, as these are recommended ahead of SSRIs for depression in autism 5
• Escitalopram (10-20 mg) is FDA-approved for adolescents ≥12 years and may be considered 1
• Avoid paroxetine due to higher sexual dysfunction rates 1

Option 2: Augmentation Approach

If partial response to current regimen:

• Cognitive behavioral therapy (CBT) augmentation has larger effect sizes than medication augmentation 1
• Pharmacologic augmentation with antipsychotics (risperidone, aripiprazole) shows evidence in treatment-resistant cases but carries metabolic risks 1

ADHD Medication Considerations

The current Adzenys (amphetamine) 12.5 mg dose requires careful evaluation:

• Amphetamines should only be prescribed when treating ADHD in suicidal adolescents, as they may reduce self-control 1
• In autism with ADHD, α2-adrenergic agonists (guanfacine, clonidine) may be more suitable than stimulants for some patients 5, 7
• Stimulants are less efficacious and have more adverse effects in ASD compared to typical ADHD 4, 7
• Consider switching to guanfacine extended-release if stimulant contributes to anxiety or agitation 1, 5, 7

Propranolol Role

Propranolol ER 80 mg addresses physical anxiety symptoms but has limited evidence for core anxiety treatment:

• Continue current dose as adjunctive therapy 1
• Does not interfere with other medications in this regimen 1

Monitoring Protocol

Implement structured weekly assessments during medication changes:

• Suicidal ideation screening at every contact (in-person or telephone acceptable) 1
• Akathisia assessment, as SSRI-induced akathisia correlates with increased suicidality 1
• Behavioral activation symptoms: restlessness, insomnia, impulsiveness, disinhibited behavior, aggression 1
• Weight and appetite monitoring given mirtazapine's effects 2, 8
• Blood pressure and pulse due to stimulant and propranolol combination 1, 9

Critical Pitfalls to Avoid

• Never abruptly discontinue SSRIs due to withdrawal risk; taper slowly if switching 1
• Do not combine with MAOIs or initiate within 14 days of MAOI discontinuation 2
• Avoid benzodiazepines, as they may increase disinhibition and suicide attempts in this population 1
• Do not substitute amphetamine products on mg-per-mg basis due to different formulations 9
• Recognize that treatment response may take 8-12 weeks for full effect, though some improvement should occur by 2-4 weeks 1

Duration of Treatment

Once adequate response achieved:

• Continue treatment for minimum 12-24 months after first episode remission 1
• Longer duration indicated given multiple comorbidities and trauma history 1
• Chronic care model approach is appropriate for this complex presentation 1